Kanaoka E[au] - Search Results

Year	Number of Results
1993	1
1994	1
1999	1
2001	1
2002	2
2003	2
2008	1
2012	2
2013	1
2014	1
2015	1
2022	0

1

Stabilization of aerosolized IFN-gamma by liposomes.

Kanaoka E, Nagata S, Hirano K. Kanaoka E, et al. Int J Pharm. 1999 Oct 25;188(2):165-72. doi: 10.1016/s0378-5173(99)00218-5. Int J Pharm. 1999. PMID: 10518672

2

The comparative disposition and metabolism of dolutegravir, a potent HIV-1 integrase inhibitor, in mice, rats, and monkeys.

Moss L, Wagner D, Kanaoka E, Olson K, Yueh YL, Bowers GD. Moss L, et al. Among authors: kanaoka e. Xenobiotica. 2015 Jan;45(1):60-70. doi: 10.3109/00498254.2014.942409. Epub 2014 Jul 18. Xenobiotica. 2015. PMID: 25034010

3

In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor.

Reese MJ, Savina PM, Generaux GT, Tracey H, Humphreys JE, Kanaoka E, Webster LO, Harmon KA, Clarke JD, Polli JW. Reese MJ, et al. Among authors: kanaoka e. Drug Metab Dispos. 2013 Feb;41(2):353-61. doi: 10.1124/dmd.112.048918. Epub 2012 Nov 6. Drug Metab Dispos. 2013. PMID: 23132334

4

A new generic column switching system for quantitation in cassette dosing using LC/MS/MS.

Ohkawa T, Ishida Y, Kanaoka E, Takahashi K, Okabe H, Matsumoto T, Nakamoto S, Tamada J, Koike M, Yoshikawa T. Ohkawa T, et al. Among authors: kanaoka e. J Pharm Biomed Anal. 2003 Apr 10;31(6):1089-99. doi: 10.1016/s0731-7085(02)00649-0. J Pharm Biomed Anal. 2003. PMID: 12667925

5

pH-sensitive liposomes composed of tocopherol hemisuccinate and of phosphatidylethanolamine including tocopherol hemisuccinate.

Jizomoto H, Kanaoka E, Hirano K. Jizomoto H, et al. Among authors: kanaoka e. Biochim Biophys Acta. 1994 Aug 4;1213(3):343-8. Biochim Biophys Acta. 1994. PMID: 8049248

6

A novel and simple type of liposome carrier for recombinant interleukin-2.

Kanaoka E, Takahashi K, Yoshikawa T, Jizomoto H, Nishihara Y, Hirano K. Kanaoka E, et al. J Pharm Pharmacol. 2001 Mar;53(3):295-302. doi: 10.1211/0022357011775523. J Pharm Pharmacol. 2001. PMID: 11291744

7

Role of Na+/L-carnitine transporter (OCTN2) in renal handling of pivaloylcarnitine and valproylcarnitine formed during pivalic acid-containing prodrugs and valproic acid treatment.

Ohnishi S, Okamura N, Sakamoto S, Hasegawa H, Norikura R, Kanaoka E, Takahashi K, Horie K, Sakamoto K, Baba T. Ohnishi S, et al. Among authors: kanaoka e. Drug Metab Pharmacokinet. 2008;23(4):293-303. doi: 10.2133/dmpk.23.293. Drug Metab Pharmacokinet. 2008. PMID: 18762717 Free article.

8

Continuous release of interleukin-2 from liposomal IL-2 (mixture of interleukin-2 and liposomes) after subcutaneous administration to mice.

Kanaoka E, Takahashi K, Yoshikawa T, Jizomoto H, Nishihara Y, Hirano K. Kanaoka E, et al. Drug Dev Ind Pharm. 2003 Nov;29(10):1149-53. doi: 10.1081/ddc-120025872. Drug Dev Ind Pharm. 2003. PMID: 14677775

9

A significant enhancement of therapeutic effect against hepatic metastases of M5076 in mice by a liposomal interleukin-2 (mixture).

Kanaoka E, Takahashi K, Yoshikawa T, Jizomoto H, Nishihara Y, Uchida N, Maekawa R, Hirano K. Kanaoka E, et al. J Control Release. 2002 Aug 21;82(2-3):183-7. doi: 10.1016/s0168-3659(02)00083-4. J Control Release. 2002. PMID: 12175736

10

Renoprotective action of a matrix metalloproteinase inhibitor in progressive mesangioproliferative nephritis.

Kuroda T, Masui M, Notoya M, Ito M, Tamura Y, Okamoto H, Kanaoka E, Shinosaki T. Kuroda T, et al. Among authors: kanaoka e. Nephron Extra. 2012 Jan;2(1):133-46. doi: 10.1159/000338801. Epub 2012 May 26. Nephron Extra. 2012. PMID: 22739248 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results